Japan patent granted

In June 2022, Tel-Array added Japan to its list of national patents granted on the Spot Profiler multiplex immunoassay platform. Other countries that have granted patents on the Spot Profiler are the USA and Australia; both these patents were granted in late 2021. Patents from 7 other jurisdictions are currently in the national examination phase and are expected to be granted throughout 2022-2023.

Australia patent granted

Following the successful patent application in the USA in October 2021, Tel-Array’s patent application was granted by the Australia Patent Office in December 2021. Patents are in the national examination phase in 8 other jurisdictions and are expected to be granted throughout 2022. We are excited at reaching these milestones and they are truly a testament of our R&D team’s achievements.

First patent granted in the USA

We are pleased to announce that Tel-Array’s patent application was granted by the United States Patent and Trademark Office (USPTO) in October 2021, making the USA the first country to grant Tel-Array’s patent. Tel-Array currently has patents in the national examination phase in 9 other jurisdictions.

Featured on BioLinks e-newsletter

Tel-Array was featured on the “members spotlight” section in the March 5, 2021 issue of the BioLinks e-newsletter. BioLinks is a twice-weekly e-newsletter produced by Lifescience BC and provides a snapshot of what is happening in the life sciences community.

Completion of initial assay performance characterization

Tel-Array is excited to announce the completion of the Spot Profiler’s initial assay performance characterization with promising results! More details to be released soon.